3[(3-Alkylamino-2-hydroxypropoxy)phenyl]-1,2-propanediols

ABSTRACT

This invention concerns novel 3-[(3-alkylamino-2-hydroxypropoxy)phenyl]-1,2-propanediols of the formula: ##STR1## wherein R is selected from the group consisting of straight or branched-chain lower alkyls (C 1  -C 6 ) and cycloalkyls (C 1  -C 6 ); R 1  and R 2  are selected from the group consisting of hydrogen and 2,3-dihydroxypropyl, with the proviso that R 1  and R 2  may not be the same; and R 3  is selected from the group consisting of lower alkyls (C 1  -C 4 ) and lower alkoxys (C 1  -C 4 ); and the acid addition salts thereof. These novel compounds are useful as antiarrhythmic agents and β-andrenergic blockers in mammals. 
     This invention also concerns novel compounds of the formula ##STR2## wherein R 1  and R 2  are selected from the group consisting of hydrogen and 2,3-dihydroxypropyl, with the proviso that R 1  and R 2  may not be the same; R 3  is selected from the group consisting of lower alkyls (C 1  -C 4 ) and lower alkoxys (C 1  -C 4 ); and X is selected from the group consisting of ##STR3## and --CHOH--CH 2  --Z (or a mixture of these compounds wherein X has both meanings stated above) where Z may be halogen, alkoxy sulfonyl and aryloxysulfonyl; and the acid-addition salts thereof. These compounds are useful as intermediates for the preparation of the active antiarrhythmic and β-andrenergic blocking compounds described above. 
     This invention also concerns a process for preparing said antiarrhythmic and β-andrenergic blocking compounds from said intermediates.



